Recent Posts
- Octuplets mom Nadya Suleman settles her workers’ comp case
- Lawsuit alleges UMC misclassified patients, overcharged millions
- Stabbing victim files civil suit against family
- Potentially deadly ice cream recalled
- Fatal I-75 crash in 2009 spawns lawsuit against Collier teacher
- Spencer Reed Group to Settle EEOC Race and Age Discrimination Lawsuit
- Sickened September 11 workers get revised settlement
- Metro sports giants clash in court
- Wrongful death lawsuit filed against 4 New Orleans cops in Henry Glover case
- Starwatch consumer | BMW, VW issue recalls
- Wrigley Settles False-Ad Class Action For $6M
- New sex abuse suit filed against Los Angeles Archdiocese
- Police, fire unions sue Baltimore over pensions
- Woman falls asleep on United flight, wakes up alone after plane lands
- Carradine’s wife sues film company
Archived Posts
- June 2010 (39)
- May 2010 (27)
- April 2010 (57)
- March 2010 (168)
- February 2010 (144)
- January 2010 (119)
- December 2009 (8)
- November 2009 (165)
- October 2009 (1)
- June 2009 (29)
- April 2009 (61)
- March 2009 (140)
- February 2009 (156)
- January 2009 (151)
- December 2008 (143)
- November 2008 (113)
- October 2008 (192)
- September 2008 (88)
- August 2008 (8)
- July 2008 (29)
Blogroll
Pages
| M | T | W | T | F | S | S |
|---|---|---|---|---|---|---|
| « Jun | ||||||
| 1 | 2 | 3 | 4 | 5 | ||
| 6 | 7 | 8 | 9 | 10 | 11 | 12 |
| 13 | 14 | 15 | 16 | 17 | 18 | 19 |
| 20 | 21 | 22 | 23 | 24 | 25 | 26 |
| 27 | 28 | 29 | 30 | |||
Meta
Data From Studies of Pfizer Neurontin Drug May Have Been Skewed
November 13, 2009
Researchers say trials of Pfizer Inc.’s Neurontin epilepsy treatment for uses that were not yet approved may have been skewed to emphasize favorable results.
Comparisons of internal company documents with published data from 12 clinical trials found inconsistencies between data that made it into the medical journals and findings from the original trials, according to a report in tomorrow’s New England Journal of Medicine. Discrepancies included reports of positive results from trials that were initially found to be negative, and primary study goals reported as secondary study goals.
Pfizer paid $430 million in criminal fines and civil penalties in 2004 for urging doctors to prescribe Neurontin for off-label uses. The drugmaker said the new review isn’t credible and the company didn’t attempt to mislead the medical community.
Read Article: Bloomberg
Posted By: Arizona Phoenix Attorneys for Accidents on the Premises of Others
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL